Bulevirtide is a Synthetic Peptide owned by Gilead Sciences, and is involved in 13 clinical trials, of which 10 were completed, and 3 are ongoing.
Myrcludex B inhibits NTCP protein. It also inhibits the infection by blocking a cell by binding to the HBV-preS1-specific receptor on the surface of the hepatocyte. Cellular receptors play an important role in viral pathogenesis. Viral nucleocapsids enter the cell and reach the nucleus, where the viral genome is delivered. The drug candidate blocks the penetration of Hepatitis B and D viruses into hepatocytes (liver cells) thus creating a reserve for the restoration of liver tissue and preventing disease progression as well as the development of complications.
The revenue for Bulevirtide is expected to reach a total of $10.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Bulevirtide NPV Report.
Bulevirtide was originated by French National Institute of Health and Medical Research and University of Heidelberg and is currently owned by Gilead Sciences.
Bulevirtide (Hepcludex) is a 47-amino acid long, n-terminally myristoylated, hepatitis B virus (HBV) envelope protein derived synthetic peptide an anti viral agent. It is formulated as powder for solution and solution for subcutaneous route of administration. Hepcludex is indicated for the treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult patients with compensated liver disease. It was also under development for the treatment of non-alcoholic steatohepatitis (NASH), dyslipidemia and primary biliary cholangitis (PBC).
Gilead Sciences Overview
Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. It has manufacturing facilities in Edmonton, Alberta, Canada; Foster City, San Dimas, Oceanside, California; and Cork, Ireland among others. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.
The company reported revenues of (US Dollars) US$27,305 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 36.3%, compared to an operating margin of 16.5% in FY2020. In FY2021, the company recorded a net margin of 22.8%, compared to a net margin of 0.5% in FY2020. The company reported revenues of US$7,042 million for the third quarter ended September 2022, an increase of 12.5% over the previous quarter.
Quick View – Bulevirtide
|Highest Development Stage|